University of Natural Resources and Life Sciences, Vienna (BOKU) - Research portal

Boosting the reduction of environmental impact of pharmaceutical products by biocatalysts, capturing of carcinogenic impurities, substitution of non-recycled solvents, reactive extrusion, and continuous manufacturing

Programme:: Horizon Europe - Global Challenges - Research & Innovation Action (RIA)

Project partners: AIMPLAS, València Parc Tecnològic Calle Gustave Eiffel, 4, 46980 Paterna, Spain.
Function of the Project Partner: Koordinator; IRIS TECHNOLOGY SOLUTIONS, SOCIEDAD LIMITADA, CALLE VELAZQUEZ, NO 94 PRIMERA PLANTA, 28006 Madrid, Spain.
Function of the Project Partner: Partner; University of Aveiro, 3810-193 Aveiro, Portugal.
Function of the Project Partner: Partner

Staff: Gübitz Georg, Project Staff; Fabbri Filippo, Project Staff; Warne Cicely May, Project Staff

Funded by: Commission of the European Communities, Rue de la Loi, Brussels, European Union

Abstract: ETERNAL aims to contribute to sustainable development of pharmaceutical manufacture, use and disposal, by using and promoting full life cycle approaches covering design, manufacture, usage, and disposal, assessing the environmental risks of not only the API and residues/metabolites, but other chemicals and by-products of the production process. This type of approach is essential to take into consideration the types of green manufacturing approach under consideration by the pharmaceutical industry, as evidenced by the range and scope of case studies being undertaken within ETERNAL. Specific application of our risk and life cycle assessment approaches to the ETERNAL case studies is a key element of the proposed work and will provide industry and policymakers with key examples of how whole life cycle assessment may be used to evaluate the changes in environmental impacts expected due to the introduction of green manufacturing processes.

Keywords: Chemistry; Environmental Biotechnology; Medical Biotechnology;; Verbleib von Pharmazeutika; green-by-design; Gesundheitswesen; Arzneimitteln; safe-by-design ;